Analysts Issue Forecasts for Alector FY2026 Earnings

Alector, Inc. (NASDAQ:ALEC) – Equities researchers at HC Wainwright issued their FY2026 earnings per share estimates for shares of Alector in a note issued to investors on Friday, November 6th. HC Wainwright analyst A. Ghosh anticipates that the company will earn $0.80 per share for the year. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for Alector’s current full-year earnings is ($0.55) per share. HC Wainwright also issued estimates for Alector’s Q4 2026 earnings at $0.12 EPS, Q1 2027 earnings at ($0.16) EPS, Q2 2027 earnings at ($0.17) EPS, Q3 2027 earnings at ($0.19) EPS, Q4 2027 earnings at ($0.19) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.58) EPS, FY2029 earnings at ($0.72) EPS and FY2030 earnings at ($0.52) EPS.

Other research analysts have also recently issued research reports about the company. Wall Street Zen upgraded Alector from a “hold” rating to a “buy” rating in a research report on Saturday. UBS Group reaffirmed a “neutral” rating and issued a $1.50 price target on shares of Alector in a report on Tuesday, October 6th. Weiss Ratings raised shares of Alector from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Finally, Morgan Stanley upped their target price on Alector from $2.00 to $3.00 and gave the company an “underweight” rating in a research note on Tuesday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.62.

Alector Stock Up 7.4%

ALEC opened at $2.46 on Tuesday. The company has a current ratio of 5.26, a quick ratio of 5.26 and a debt-to-equity ratio of 0.80. Alector has a one year low of $1.09 and a one year high of $2.76. The business’s fifty day moving average is $2.06 and its two-hundred day moving average is $2.04.

Alector (NASDAQ:ALEC) last issued its quarterly earnings data on Thursday, November 5th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $1.34. The firm had revenue of $162.87 million during the quarter, compared to analysts’ expectations of $2.19 million. Alector had a negative return on equity of 531.03% and a negative net margin of 850.13%.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ALEC. Russell Investments Group Ltd. grew its stake in Alector by 8.2% in the third quarter. Russell Investments Group Ltd. now owns 106,614 shares of the company’s stock worth $197,000 after purchasing an additional 8,118 shares in the last quarter. Nantahala Capital Management LLC acquired a new stake in shares of Alector in the 2nd quarter worth about $8,679,399. Public Employees Retirement System of Ohio acquired a new stake in Alector in the 2nd quarter valued at approximately $241,000. Bank of America Corp DE acquired a new position in Alector during the 2nd quarter valued at about $287,000. Finally, Elmind Capital LP bought a new stake in shares of Alector in the 2nd quarter worth $1,809,000. 85.83% of the stock is currently owned by institutional investors.

Insider Transactions at Alector

In related news, CEO Arnon Rosenthal sold 72,606 shares of Alector stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $2.66, for a total transaction of $193,131.96. Following the sale, the chief executive officer owned 2,294,600 shares of the company’s stock, valued at $6,103,636. The trade was a 3.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Neil Berkley sold 29,251 shares of the business’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $2.66, for a total value of $77,807.66. Following the completion of the transaction, the chief financial officer owned 350,649 shares in the company, valued at approximately $932,726.34. This trade represents a 7.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 111,303 shares of company stock valued at $295,633. Insiders own 8.30% of the company’s stock.

Key Stories Impacting Alector

Here are the key news stories impacting Alector this week:

• Positive Sentiment: HC Wainwright forecasts EPS of $0.80 for FY2026, including $0.12 in Q4, versus the current full-year consensus estimate of a $0.55 loss. The firm’s Strong-Buy rating may bolster investor sentiment.
• Negative Sentiment: The analyst expects losses to resume: EPS forecasts are ($0.61) for FY2027, ($0.58) for FY2028, ($0.72) for FY2029, and ($0.52) for FY2030. These projections temper the near-term optimism.

Alector Company Profile

Alector, Inc (NASDAQ: ALEC) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s research platform, known as immuno-neurology, is designed to use the body’s immune system to protect or restore the brain’s ability to maintain healthy neural connections.

Alector’s investigational pipeline has included antibody-based treatments for conditions such as frontotemporal dementia and Alzheimer’s disease. Its programs have targeted biological pathways associated with neurodegeneration, including progranulin and TREM2.